^
Association details:
| Biomarker: | EGFR mutation + MET overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Response to tyrosine kinase inhibtors in non-small-cell lung cancer with concomitant c-MET overexpression and driver genes.
Excerpt:
Advanced NSCLC patients with concomitant EGFR mutation and MET overexpression have significantly low RR with EGFR-TKIs, indicating that MET overexpression potentially causes intrinsic resistance to EGFR-TKIs.
